158 related articles for article (PubMed ID: 26282406)
1. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.
Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA
BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406
[TBL] [Abstract][Full Text] [Related]
2. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
3. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).
Wu J; Clingen PH; Spanswick VJ; Mellinas-Gomez M; Meyer T; Puzanov I; Jodrell D; Hochhauser D; Hartley JA
Clin Cancer Res; 2013 Feb; 19(3):721-30. PubMed ID: 23251007
[TBL] [Abstract][Full Text] [Related]
4. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
5. DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057.
Hartley JA; Hamaguchi A; Suggitt M; Gregson SJ; Thurston DE; Howard PW
Invest New Drugs; 2012 Jun; 30(3):950-8. PubMed ID: 21384134
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats.
Reid JM; Buhrow SA; Kuffel MJ; Jia L; Spanswick VJ; Hartley JA; Thurston DE; Tomaszewski JE; Ames MM
Cancer Chemother Pharmacol; 2011 Sep; 68(3):777-86. PubMed ID: 21188379
[TBL] [Abstract][Full Text] [Related]
7. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
Wilkinson GP; Taylor JP; Shnyder S; Cooper P; Howard PW; Thurston DE; Jenkins TC; Loadman PM
Invest New Drugs; 2004 Aug; 22(3):231-40. PubMed ID: 15122070
[TBL] [Abstract][Full Text] [Related]
8. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling.
Arnould S; Spanswick VJ; Macpherson JS; Hartley JA; Thurston DE; Jodrell DI; Guichard SM
Mol Cancer Ther; 2006 Jun; 5(6):1602-9. PubMed ID: 16818520
[TBL] [Abstract][Full Text] [Related]
10. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
Gregson SJ; Howard PW; Hartley JA; Brooks NA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
J Med Chem; 2001 Mar; 44(5):737-48. PubMed ID: 11262084
[TBL] [Abstract][Full Text] [Related]
12. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.
Hartley JA; Hamaguchi A; Coffils M; Martin CR; Suggitt M; Chen Z; Gregson SJ; Masterson LA; Tiberghien AC; Hartley JM; Pepper C; Lin TT; Fegan C; Thurston DE; Howard PW
Cancer Res; 2010 Sep; 70(17):6849-58. PubMed ID: 20660714
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120.
Walton MI; Goddard P; Kelland LR; Thurston DE; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(5):431-8. PubMed ID: 8765436
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
Puzanov I; Lee W; Chen AP; Calcutt MW; Hachey DL; Vermeulen WL; Spanswick VJ; Liao CY; Hartley JA; Berlin JD; Rothenberg ML
Clin Cancer Res; 2011 Jun; 17(11):3794-802. PubMed ID: 21346148
[TBL] [Abstract][Full Text] [Related]
15. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies.
Martin C; Ellis T; McGurk CJ; Jenkins TC; Hartley JA; Waring MJ; Thurston DE
Biochemistry; 2005 Mar; 44(11):4135-47. PubMed ID: 15766241
[TBL] [Abstract][Full Text] [Related]
16. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.
Hochhauser D; Meyer T; Spanswick VJ; Wu J; Clingen PH; Loadman P; Cobb M; Gumbrell L; Begent RH; Hartley JA; Jodrell D
Clin Cancer Res; 2009 Mar; 15(6):2140-7. PubMed ID: 19276288
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models.
Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY
BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279
[TBL] [Abstract][Full Text] [Related]
20. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136.
Clingen PH; De Silva IU; McHugh PJ; Ghadessy FJ; Tilby MJ; Thurston DE; Hartley JA
Nucleic Acids Res; 2005; 33(10):3283-91. PubMed ID: 15944449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
